Skip to main content
. 2020 Nov 24;4(22):5836–5845. doi: 10.1182/bloodadvances.2020002872

Table 1.

Baseline characteristics of patients recruited to Myeloma XI by treatment pathway

Characteristics Total Intensive pathway Nonintensive pathway P
N or n (%) 4158 2435 (58.5) 1723 (41.4)
Age, y
 Median (IQR) 71 (78-64) 65 (70-59) 79 (83-75) <.001
Sex, n (%)
 Male:female 2439 (59):1719 (41) 1462 (60):973 (40) 977 (57):746 (43) .031
Ethnicity, n (%)
 White: others 3880 (93):278 (7) 2255 (93):180 (7) 1625 (94):98 (6) .199
Myeloma type, n (%)
 IgG 2252 (54) 1296 (53) 956 (55.5) .001
 IgA 919 (22) 519 (21) 400 (23.2)
 LCO 491 (12) 325 (13) 166 (9.6)
 No paraprotein 32 (0.8) 20 (0.8) 12 (0.7)
 IgD 42 (1) 33 (1.4) 9 (0.5)
 IgM 8 (0.2) 6 (0.2) 2 (0.1)
 Missing 414 (10) 236 (9.7) 178 (10.4)
FLC isotype, n (%)
 κ 2449 (59) 1421 (58.4) 1028 (60) .177
 λ 1260 (30) 757 (31) 503 (29)
 Missing 449 (11) 257 (10) 192 (11)
dFLC κ, mg/L
 Median (IQR) 320 (44-984) 292 (40-901) 370 (72.5-1124) .008
dFLC λ, mg/L
 Median (IQR) 406 (69-1127) 429 (69-1143) 380 (63-1098) .575
Baseline eGFR, mL per min per 1.73 m2
 Median (IQR) 64 (49-81) 68 (54-85) 58 (44-75) <.001
Baseline eGFR, n (%), mL per min per 1.7 3 m2
 eGFR >59 2271 (55) 1514 (62) 757 (44) <.001
 eGFR 30-59 1366 (33) 658 (27) 708 (41)
 eGFR <30 256 (6.2) 122 (5) 134 (7.7)
 Missing 265 (6.4) 141 (6) 124 (7)
Baseline dFLC, n (%), mg/L
 <500 2314 (56) 1379 (57) 935 (54) <.001
 500-1000 596 (14) 356 (15) 240 (14)
 ≥1001 995 (24) 559 (23) 436 (25)
 Missing 253 (6) 141 (6) 112 (6.5)
dFLC response, n (%)
 <50% 125 (3) 34 (1.4) 91 (5.2) <.001
 50%-90% 290 (7) 86 (3.5) 204 (12)
 >90% 1239 (30) 879 (36.1) 360 (21)
 Baseline dFLC <100 1160 (28) 718 (29.4) 442 (25.6)
 Missing 1344 (32) 718 (29.4) 626 (36.3)

Boldface P values signify statistical significance (P < .05).

Ig, immunoglobulin; LCO, light chain only.